HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Abstract
Inhibition of angiogenesis may have wide use in the treatment of cancer; however, this approach alone will not cause tumor regression but may only slow the growth of solid tumors. The clinical potential of antiangiogenic agents may be increased by combining them with conventional chemotherapeutics. 4-[4-(1-Amino-1-methylethyl)phenyl]-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]pyrimidine-5-carbonitrile (JNJ-17029259) represents a novel structural class of 5-cyanopyrimidines that are orally available, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2) and other tyrosine kinases involved in angiogenesis, such as platelet-derived growth factor receptor, fibroblast growth factor receptor, VEGF-R1, and VEGF-R3, but have little activity on other kinase families. At nanomolar levels, JNJ-17029259 blocks VEGF-stimulated mitogen-activated protein kinase signaling, proliferation/migration, and VEGF-R2 phosphorylation in human endothelial cells; inhibits the formation of vascular sprouting in the rat aortic ring model of angiogenesis; and interferes with the development of new veins and arteries in the chorioallantoic membrane assay. At higher concentrations of 1 to 3 microM, this compound shows antiproliferative activity on cells that may contribute to its antitumor effects. JNJ-17029259 delays the growth of a wide range of human tumor xenografts in nude mice when administered orally as single-agent therapy. Histological examination revealed that the tumors have evidence of reduced vascularity after treatment. In addition, JNJ-17029259 enhances the effects of the conventional chemotherapeutic drugs doxorubicin and paclitaxel in xenograft models when administered orally in combination therapy. An orally available angiogenesis inhibitor that can be used in conjunction with standard chemotherapeutic agents to augment their activity may have therapeutic benefit in stopping the progression of cancer and preventing metastasis.
AuthorsStuart Emanuel, Robert H Gruninger, Angel Fuentes-Pesquera, Peter J Connolly, Jennifer A Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R D'Andrea, Michael Reuman, Gilles Bignan, Robert Tuman, Dana Johnson, David Moffatt, Mark Batchelor, Anne Foley, James O'Connell, Rodger Allen, Martin Perry, Linda Jolliffe, Steven A Middleton
JournalMolecular pharmacology (Mol Pharmacol) Vol. 66 Issue 3 Pg. 635-47 (Sep 2004) ISSN: 0026-895X [Print] United States
PMID15322256 (Publication Type: Journal Article)
Chemical References
  • 4-(4-(1-Amino-1-methylethyl)phenyl)-2-(4-(2-morpholin-4-yl-ethyl)phenylamino)pyrimidine-5-carbonitrile
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Nitriles
  • Pyrimidines
  • Doxorubicin
  • Vascular Endothelial Growth Factor Receptor-2
  • Paclitaxel
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cell Division (drug effects)
  • Cell Movement (drug effects)
  • Doxorubicin (therapeutic use)
  • Drug Therapy, Combination
  • Endothelium, Vascular (drug effects, physiology)
  • Enzyme Inhibitors (therapeutic use)
  • Humans
  • Mice
  • Neoplasms, Experimental (drug therapy)
  • Nitriles (pharmacology, therapeutic use)
  • Paclitaxel (therapeutic use)
  • Pyrimidines (pharmacology, therapeutic use)
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: